Date:9/7/2010

current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended June 30, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Yasmin® is a registered trademark of Bayer Schering Pharma Aktiengesellschaft.CONTACTS:Investors:Patty EisenhaurWatson Pharmaceuticals, Inc. (973) 355-8141Media:Charlie MayrWatson Pharmaceuticals, Inc. (973) 355-8483(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO)

'/>"/>

SOURCE Watson Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
2. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
3. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
4. Perrigo Confirms Filing for Generic Version of Gynazole-1® Cream and Announcement of Patent Infringement Lawsuit by KV Pharma
5. Mylan Launches the Generic Version of Solodyn®, 45 mg, 90 mg and 135 mg Tablets, Announces Settlement Agreement with Medicis
6. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Flomax®
7. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets
8. Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin®
9. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Optivar®
10. Watsons Generic Prograf® 5 mg Receives FDA Approval
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Exelon® Capsules